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Abstract
Background: Genome-wide association studies have implicated the transcription factor 7-like 2 (TCF7L2) gene in
type 2 diabetes risk, and more recently, in decreased body mass index. Given the contrary direction of genetic
effects on these two traits, it has been suggested that the observed association with body mass index may reflect
either selection bias or a complex underlying biology at TCF7L2.
Methods: Using 9031 Hispanic/Latino adults (21–76 years) with complete weight history and genetic data from the
community-based Hispanic Community Health Study/Study of Latinos (HCHS/SOL, Baseline 2008–2011), we estimated the
multivariable association between the additive number of type 2 diabetes increasing-alleles at TCF7L2 (rs7903146-T) and
body mass index. We then used structural equation models to simultaneously model the genetic association on changes
in body mass index across the life course and estimate the odds of type 2 diabetes per TCF7L2 risk allele.
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Results: We observed both significant increases in type 2 diabetes prevalence at examination (independent of body mass
index) and decreases in mean body mass index and waist circumference across genotypes at rs7903146. We observed a
significant multivariable association between the additive number of type 2 diabetes-risk alleles and lower body mass
index at examination. In our structured modeling, we observed non-significant inverse direct associations
between rs7903146-T and body mass index at ages 21 and 45 years, and a significant positive association
between rs7903146-T and type 2 diabetes onset in both middle and late adulthood.
Conclusions: Herein, we replicated the protective effect of rs7930146-T on body mass index at multiple time points in
the life course, and observed that these effects were not explained by past type 2 diabetes status in our structured
modeling. The robust replication of the negative effects of TCF7L2 on body mass index in multiple samples, including in
our diverse Hispanic/Latino community-based sample, supports a growing body of literature on the complex biologic
mechanism underlying the functional consequences of TCF7L2 on obesity and type 2 diabetes across the life course.
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Background
Hispanic/Latino adults in the United States (US) are dis-
proportionally affected by obesity and it consequences
such as type 2 diabetes (T2D) [1] and this disparity is
widening as compared to non-Hispanic Whites [2]. The
transcription factor-7 like 2 gene (TCF7L2) was the first
locus to be associated with T2D in genome-wide associ-
ation studies (GWAS) and has been consistently associ-
ated with T2D [3, 4], TCF7L2 (previously known as
TCF4) encodes a transcription factor that is an effector
of the Wnt signaling pathway [5]. Although the under-
lying biological mechanisms of TCF7L2 remain unclear
[6], the consistent association between the TCF7L2 locus
and T2D has been generalized to many diverse popula-
tions including Hispanic/Latinos [7, 8]. Indeed, the asso-
ciated risk allele, rs7903146-T, harbored within the
fourth intron of TCF7L2 has the largest effect on T2D
risk of all GWAS-identified T2D loci reported to date
[8]. In Hispanic/Latinos each risk-allele has been associ-
ated with a 40% increased odds of T2D [7, 9].
The T2D-increasing allele at TCF7L2 has also been as-
sociated with lower body mass index (BMI) [3, 10–12],
resulting in a subsequent call for future research [13]
given the strong epidemiologic correlation between in-
creasing BMI and risk of T2D [14]. This association has
been attributed to a T2D-related ascertainment bias,
mainly due to the observation that the strongest and
most significant TCF7L2 associations with BMI are seen
in T2D cases/controls, as compared to population-based
studies [15–17].
There is mounting evidence of a complex biologic
story for TCF7L2, explained in part by the bidirectional
action of TCF7L2 that may be cell, tissue or metabolic-
ally dependent [5]. Functional studies indicate that the
rs7903146 variant may act in a cell or tissue-specific
manner [18], by influencing alternative splicing of the
TCF7L2 [19–21], or by binding affinity of complex tran-
scriptional machinery at an open chromatin region
specific to human pancreatic islets [22–25] to modulate
pancreatic islet cell insulin production and secretion
[17], action in adipose tissue [26], hepatic glucose output
[27] or intestinal tissue differentiation [28]. Observa-
tional studies indicate that the T2D risk allele at TCF7L2
associates with decreases insulin secretion [29–31].
Thus, we may expect individuals with the T allele have
lower BMI values on average, and perhaps a differential
pattern of insulin resistance.
Due to the mounting evidence on potential selection
bias and the multi-faceted action of TCF7L2 variation
on insulin and glucose biology [5, 6, 18], we aimed 1) to
replicate the multivariable association between TCF7L2
T2D risk alleles and lower BMI in a population-based
study of US Hispanic/Latinos accounting for key covari-
ates, and 2) to model the structured pathways between
rs7903146, at TCF7L2, BMI over time, and age of dia-
betes diagnosis. We performed these analyses in 9031
self-identified Hispanic/Latino adults (21–76 years of
age at examination) residing in four US urban centers,
who consented to genotyping and provided weight his-
tory and T2D diagnosis information the Hispanic
Community Health Study/Study of Latinos (HCHS/
SOL) baseline examination (2008–2011).
Methods
Study participants
We used data from the HCHS/SOL study, a multi-center,
longitudinal, household-based cohort study of 16,415
Hispanic/Latino adults, aged 18–76 years in 2008–2011,
who were sampled using a two-stage probability design
from four US urban communities (The Bronx, NY;
Chicago, IL; Miami, FL; San Diego, CA), as described
previously in detail [32, 33]. Briefly, the complex sampling
design allowed researchers to 1) over-sample individuals
≥45 years of age who were most likely to experience cardio-
metabolic disease outcomes either by the baseline examin-
ation or during follow up, while 2) capturing the varied
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socioeconomic and demographic composition of Hispanic/
Latino households (as per the 2000 Census block group
proportion of residents ≥25 years old with at least a high
school education and the proportion Hispanic/Latino resi-
dents) and efficiently estimating cardiometabolic disease
across the four Hispanic/Latino communities under study.
Centrally-trained study personnel conducted the screening
and baseline examinations in either English or Spanish
based on participant preference.
Body mass index
As part of the HCHS/SOL baseline examination [32],
current body weight was self-reported (in whole lb. or kg)
and measured (to a tenth of a kg) and height was mea-
sured (to whole cm) on participants who were able to
stand on both feet. As described previously [34], the ac-
curacy and reliability of the self-reported weights were
good (mean differenceself-report–measured = 0.23 kg, r
2 = 0.97;
inter-rater reliability coefficients, 0.93 and 0.97). Waist
circumference was measured in cm at the umbilicus using
a tape measure, and body fat percentage estimated by a
Tanita Body Composition Analyzer.
Additionally, a weight history questionnaire was used
to collect self-reported body weights (in whole lb. or kg,
while not pregnant) at 21, 45, and 65 years of age, for
individuals 21 years or older at baseline. If participants
indicated that they could not remember their exact
weight, personnel were instructed to inquire about their
best guess. The quality control procedures and data
cleaning are described in the Appendix. We converted
each weight from the weight histories to kg and rounded
each weight to the whole unit, to eliminate measurement
error by unit of report (e.g. lb. or kg).
We excluded all weights from women who reported
currently being pregnant at baseline or individuals with
limb amputations that otherwise did not limit their ability
to stand (Additional file 1: Figure S2 and Table S1). Using
measured height at baseline, we calculated two baseline
BMI measures (kg/m2) and up to three BMIs from the
weight histories of individuals at least 21 years of age (cor-
responding to 21, 45, and 65 years). We further excluded
any BMI that was less < 16 or > 70 kg/m2. As measured
height is an imperfect proxy of an individual’s height at
various times in the past, all models of BMI from the
weight histories (at 21, 45, and 65 years) also accounted for
the age at baseline as a measure of age at time of recall.
Type 2 diabetes assessment
HCHS/SOL participants were asked to bring in the med-
ications they were currently taking, during the baseline
examination. Individuals were also asked to report if a
“doctor ever said that you have diabetes (high sugar in
blood or urine)” and the age when this diagnosis was re-
ceived. Participants were asked to fast overnight (> 8 h)
and their glucose was measured in the entire sample,
and 2-h post-oral glucose tolerance tests was measured
among those who reported never having received a diabetes
diagnosis. Impaired fasting glucose among non-diabetics
was defined as a fasting glucose 100-125 mg/dL or 140-199
mg/dL after oral glucose challenge. We used the American
Diabetes Association definition to identify T2D cases at
examination based on fasting glucose (≥126 mg/dL), an
oral glucose tolerance test (OGTT, ≥200 mg/dL), per-
cent Glycated Hemoglobin (HbA1C ≥6.5%), or dia-
betes medications [35]. Controlled diabetes was
further defined as % HbA1C < 7%.
Type of diabetes was not reported in HCHS/SOL.
Therefore, we used information on age at diabetes diag-
nosis to create age period-specific T2D diagnosis indica-
tors. If an individual was younger than 45 or 65 years at
the baseline examination, then the classification of T2D
diagnosis of the incomplete age period was set to miss-
ing (e.g. for a 50-year-old, T2D diagnosis for the period
of 22–45 years could be yes/no, but would be set to
missing for 46–65 years).
Genetic information
Venous blood samples were collected and for all fully
consenting participants (i.e. those agreeing to genotyping
and sharing of information with HCHS/SOL investigators,
those not affiliated with HCHS/SOL, and specialized
laboratories) and were analyzed using the MetaboChip
(Illumina, Inc., San Diego, CA) (N = 12,209 or 74% of the
cohort). The MetaboChip array contains approximately
200,000 single nucleotide polymorphisms (SNPs) at 257
genomic regions previously associated with cardiometa-
bolic traits, including the TCF7L2 region that includes 258
SNPs across over 76,159 bp [36]. HCHS/SOL participants
used in this study were genotyped at the Human Genetics
Center of the University of Texas-Houston (Houston, TX)
and passed person-level quality control filters (< 95% call
rate, sex discordance or duplicate).
Based on previous trans-ethnic fine-mapping studies
with T2D [37] and BMI [15], we selected rs7903146 as
our presumed functional variant of interest at TCF7L2
as it was in strong linkage disequilibrium with several
other variants in the area (Additional file 1: Figure S1).
In HCHS/SOL, this SNP also had satisfactory quality
control measures [38], was in Hardy-Weinberg-Equilibrium
(P value = 0.10), and available in the entire sample that
passed genetic quality control procedures (n = 12,117). We
created an additive score of the number of T2D risk alleles
[7, 8] per individual at rs7903146 (e.g. CC = 0, CT = 1,TT =
2). To aid in the interpretability of adjustments for popula-
tion stratification, we adjusted for continental ancestry pro-
portions, which as reported on previously [39] were
designed to represent four a priori-selected ancestral popu-
lations using a supervised analysis (K = 4; unrelated
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1000 Genomes references representing European: CEU;
African: YRI; Northern: MXL; Caribbean/Southern Native
American Ancestry: PUR, CLM) in the program ADMIX-
TURE [40] on a pruned set of more than 45,000
MetaboChip SNPs in low linkage disequilibrium in
our sample (r2 < 0.5). Lastly, we also adjusted for the
‘genetic analysis group’ variable from the multidimensional
clustering of self-reported Hispanic/Latino background
and principal components from genome-wide data on a
majority-overlapping sample of 12,803 HCHS/SOL partic-
ipants (> 99% call rate), as described previously [39].
Statistical analyses
As shown in Fig. 1, of the entire HCHS/SOL baseline
cohort of 16,415 participants, 16,322 individuals had
self-reported and measured weight values that passed
quality control (additional information provided as part
of Additional file 1: Figure S2 and Table S1). Of the
12,209 individuals providing their full informed consent
for genotyping and data sharing, 12,117 passed genetic
quality control, as described above. The union of these
two quality controlled data sets included 12,073 individ-
uals (Fig. 1), from which we excluded 87 individuals who
reported diabetes diagnosis prior to 22 years of age, to
restrict our analysis to those for which a diabetes diagnosis
was more likely to be T2D, and 1054 individuals that did
not have both a measured current height or at least one
self-reported weight at 21, 45 or 65 years and who were
therefore unable to contribute to our structural equation
modeling. Individuals with missing covariate information,
such as missing genetic analysis group (N = 122) or infor-
mation on their highest education level achieved (catego-
rized as less than or at least a high school diploma or
equivalency) (N = 14), were excluded. Lastly, as described
previously in HCHS/SOL we used an identity-by-descent
analysis in PLINK [41] to identify close relatives (e.g. 0.35
< π < 0.98) [42], and exclude the individual in each pair
with the least weight measurements (N = 1765). A total of
9031 individuals remained in the final analytic dataset
used for all analyses, and we described their characteristics
using descriptive statistics such as means, 95% confidence
intervals (CIs), and frequencies.
Fig. 1 Flowchart of Quality Control and Exclusions Applied to the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) Cohort of
16,415 Individuals (18–76 years), which Resulted in a Final Analytic Sample of 9031 Hispanic/Latino Adults (21–76 years), Which Are Detailed
Further in the Additional file 1: Table S1 and Figure S2*
Fernández-Rhodes et al. BMC Obesity  (2018) 5:26 Page 4 of 12
Next, we modeled the association between the additive
number of rs7903146-T alleles with multiple BMI measures
using multivariable models (e.g. measured and self-reported
BMI at baseline, as well as BMI for ages 21, 45 and
65 years), controlling for age at examination, sex, educa-
tional attainment, admixture proportions, and genetic ana-
lysis group. As an exploratory analysis, we also examined
the multivariable associations with the measured BMI
stratified by previous diabetes diagnosis, as well as glucose
tolerance and diabetic medication at examination.
Using structural equation models, we then examined
an a priori-specified set of pathways (Additional file 1:
Figure S3) between the additive number of rs7903146-T
alleles, BMI (at age 21, 45 and 65), and self-reported
T2D status (between ages 22–45 and between ages 46–
65). BMI was assumed to be directly associated with
T2D status in the period immediately after the BMI
measurement (between ages 22–45 or 46–65). Similarly,
T2D status during the period of time immediately pre-
ceding a given BMI (e.g. T2D between 22 and 45 years
and 45-year-old weight) was assumed to be directly asso-
ciated with the BMI at that time. Direct pathways between
rs7903146 to BMIs and T2D measurements were also
included. BMI at the previous age was assumed to be
directly related to BMI at the following age. Age at base-
line examination (age at time of recall), sex, education
level, admixture proportions and genetic analysis group,
and were included in all pathways to BMI and T2D.
All analyses accounted for the HCHS/SOL complex
sampling design, including primary sampling unit, strata
and sampling weights, yielding valid estimates of the
disease distribution in the source population. Descriptive
statistics were estimated using SAS 9.3 (Research Tri-
angle Park, NC). All multivariable and structural equation
models were estimated using Mplus 7.11 software [43],
using full-information maximum likelihood methods to
account for missing outcome data. Additionally, we identi-
fied our analysis subpopulation (N = 9031), or the subpop-
ulation of interest in any stratified models, and used the
complex sampling information on the entire cohort in the
variance calculations to ensure valid estimates for the
source population of HCHS/SOL.
Results
Our weighted sample included women (50%) and men,
an average age of 44 years at baseline examination
(Table 1). Five percent of those who were at least 45 years
old (unweighted n = 5605) received a T2D diagnosis by
age 45 (Table 1). In the subsample of participants who
were at least 65 years of age (n = 729), 23% reported re-
ceived a diabetes diagnosis by age 65, with 3% being
diagnosed by age 45 and 20% diagnosed between ages
46–65 years. Average BMIs increased across age of recalled
weight (24 kg/m2 at 21 years to 29 kg/m2 at 65 years).
The number of T2D-risk alleles at rs7903146 associated
with an increase in T2D prevalence by 7% (P value = 0.0002)
and decreased obesity prevalence by 3–5%, based on either
the use of measured or self-reported weights (P value < 0.04,
Table 2). Mean BMI and waist circumference at examination
showed similar quantitative decreases by 0.5–0.6 kg/m2
and 1.1 cm as the number of T2D-risk allele increased
(P values< 0.1). Additionally, among the subsample
without a past diagnosis of T2D, at examination mean
OGTT glucose levels increased by (4 mg/dL difference;
P value = 0.06) and HOMA Index of Beta Cell function
decreased (12 point difference; P value = 0.07). Other
T2D-related measures, such as fasting glucose, insulin,
and HbA1C exhibited similar trends across genotypes, but
these trends were not statistically significant (P values ≥
0.1). Further stratification of BMIs by T2D status/age
at examination suggested that both increased age and
T2D status corresponded to higher average BMIs, re-
gardless of the timing of T2D diagnosis (Table 3).
The subset of participants > 65 years at examination
self-reported weights corresponding to a mean BMI in-
crease of 2.8 kg/m2 between 45 and 65 years of age among
those without T2D at baseline, and of up to 3.4 kg/m2
among those that were diagnosed with T2D after age 65.
Multivariable association analyses
We observed an association between the rs7903146
T2D-increasing allele and lower BMI, after adjustment
for age, sex, education level, admixture proportions,
and genetic analysis group. Specifically, we found that
each T allele associated with lower BMI at examination
(21–76 years), based on either measured or self-reported
weight (Table 4). As described previously [15], we also ob-
served significant inverse associations between each
rs7903146-T allele and BMI (− 0.37 kg/m2, 95% CI: -0.69,
− 0.06). Additionally, we also observed non-significant
multivariable associations between rs7903146-T and lower
BMIs at 21, and 45 years of age, and non-significant
increases in BMI at 65 years of age.
Using data from the baseline examination, we also ran
these BMI models stratified by previous diabetes diagnosis,
glucose tolerance and medication status at the baseline
examination (Additional file 1: Table S2). Weaker effects
per allele on BMI were estimated among participants who
reported having diabetes at examination as compared to
those without diabetes, regardless of the use of measured
or self-reported BMI at examination (− 0.30 to − 0.17
versus − 0.45 to − 0.48 kg/m2 per allele). Compared to our
significant protective effect on BMI among all individuals
without a prior diabetes diagnosis (− 0.45 kg/m2 per allele),
the subset of individuals who had impaired fasting glucose
or undiagnosed T2D at the examination (N = 4284)
appeared to have an even stronger protective estimated
effect on BMI (− 0.66 and − 0.85 kg/m2, respectively).
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No significant effects were seen for individuals taking
diabetes medication at examination.
Structured association analyses
In a structural equation model, we noted that each T
allele at rs7903146 was directly associated with a 1.32
(95% CI: 1.05, 1.67) higher odds of T2D diagnosis between
the ages of 22 and 45 years, and a 1.67 (95% CI: 1.15, 2.42)
higher odds of T2D diagnosis between 22 and 65 years of
age. We did not find any significant direct associations
between the rs7903146-T and BMI at any age; however,
the direction of estimated effect was inverse on BMI at 21
and 45 years (Fig. 2). Furthermore, we found no evidence
of indirect associations between rs7903146 and either
BMI or T2D at any time point (Additional file 1:
Table S3). Similarly, the indirect association between
rs7903146 and BMI at 45 and 65 years, as mediated
through a previous T2D diagnosis, was negative but
non-significant (Additional file 1: Table S4).
Discussion
In this study we successfully replicated the previous-
ly-reported association between T2D risk alleles at
TCF7L2 (rs7903146-T) and decreased BMI [3, 10–12],
within a population-based cohort of US Hispanic/Latino
adults of multiple background groups living in four urban
communities (21–76 years of age at examination). We also
observed consistently protective, albeit non-significant,
associations on BMI at 21 and 45 years. In contrast,
among the subset of individuals 65 years or older, the
non-significant association between T2D-risk variants and
BMI at 65 years of age was positive.
Next, we employed a structural equation model to exam-
ine the direct and indirect pathways between rs7903146,
T2D and BMI, which revealed that this suggestive protect-
ive effect between T2D-risk variants and BMI at 21 and
45 years of age remained even after controlling for earlier
BMI. These results collectively suggest that there may be a
persistent independent protective effect of TCF7L2 T2D
risk alleles on BMI across most of adulthood. In contrast to
a previous cross-sectional study of 1235 Hispanic/La-
tinos, which estimated a larger effects of T2D-risk al-
leles at TCF7L2 on BMI by adjusting for concurrent
T2D status (− 0.3 to − 1.1 kg/m2 for rs12255372-T) [12],
our large and diverse study of US Hispanic/Latinos
estimated more modest effects of T2D-risk alleles on BMI
(− 0.4 kg/m2 for rs7903146-T; unadjusted for T2D status)
and leveraged information on weight and T2D histories
collected during the HCHS/SOL baseline examination to
further decompose the complex relationships between
prior BMI and T2D (Effect of each T2D-risk allele on BMI
ranged from − 0.2 to 0.2 kg/m2 at 21 and 65 years of age,
respectively).
Our findings shed light on the two predominant hy-
potheses put forth to explain the inverse direction of
association between T2D and BMI at TCF7L2, as captured
by variation in rs7903146. First, it has been suggested that
case ascertainment bias [17] may drive the association of
Table 1 Weighted Descriptive Statistics of Hispanic Community Health Study/Study of Latinos Baseline (2008–2011) Analytic Sample
of 9031 Adults (21–76 years) from Four Urban United States Centers: The Bronx, NY; Chicago, IL; Miami, FL; San Diego, CA
Unweighted Analytic Sample Size and Weighted Frequency or Means (95% Confidence Interval)
Female (%) n = 5187 50%
Mean (95% CI) Age at Baseline Examination n = 9031 43.67 (43.12, 44.21)
Has High School Diploma or Equivalency (%) n = 5768 69%
Genetic Analysis Group (%) South American (n = 676) 6%
Central American (n = 1069) 8%
Cuban (n = 1764) 27%
Dominican (n = 797) 9%
Mexican (n = 3169) 33%
Puerto Rican (n = 1556) 17%
rs7903146 Genotype Frequency (%) CC (n = 5040) 55%
CT (n = 3373) 38%
TT (n = 618) 7%
Mean (95% CI) BMI (kg/m2) At 21 Years (n = 8759) 23.77 (23.61, 23.93)
At 45 Years (n = 5605) 27.48 (27.30, 27.66)
At 65 Years (n = 729) 28.99 (28.46, 29.53)
% with Self-Reported Diabetes Diagnosis Between the Ages of 22 and 45 Years 5%
Between the Ages of 46 and 65 Years 23%
Abbreviations: BMI body mass index, 95% CI 95% confidence interval
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TCF7L2 T2D risk alleles and lower BMI, as previous
GWAS have shown attenuated effects of TCF7L2 on BMI
among population-based samples as compared to the
effect sizes in samples of T2D cases [15]. Specifically,
collider stratification may bias the TCF7L2-BMI associ-
ation downwards when the ratio T2D cases to controls
has been distorted to over-represent cases, or cases with
more favorable insulin resistance profiles [44]. The active
HCHS/SOL community engagement, household sampling,
and location of clinic sites in the local community all served
to minimize selection bias.
The consistent negative association between T2D risk
alleles and BMI in early and mid-adulthood seen in this and
previous work [3, 10, 11] may point to another explanation.
A growing body of literature implicates pleiotropy at
TCF7L2 in both T2D and BMI [5]. We observed protective
associations on BMI at 21 and 45 years of age, which were
not explained by accounting for indirect pathways through
T2D or earlier BMI in our structured modeling. This work
leverages detailed weight history data to provide further
evidence for a complex mechanism underlying TCF7L2
action across the life course that may explain its associations
Table 2 Anthropometric Measures (Body Mass Index; Weight; Height; Waist Circumference; Overall and Abdominal Obesity;
Percentage Body Fat), Fasting Insulin and Glucose, Post-Oral Glucose Tolerance Test Response, and Diabetic Control Characteristics
Weighted Means (Standard Deviations) or Frequencies across rs7903146 Genotypes (n = 9031) at the Hispanic Community Health
Study/Study of Latinos Baseline Examination
CC CT TT P-value
Unweighted total analytic sample size n = 5040 n = 3373 n = 618
Measured BMIa (kg/m2) 29.74 (0.17) 29.26 (0.13) 29.21 (0.28) 0.06
Self-Reported BMIa (kg/m2) 29.81 (0.17) 29.34 (0.13) 29.23 (0.27) 0.05
Measured Weight (kg) 80.09 (0.52) 78.71 (0.39) 78.58 (0.79) 0.1
Self-Reported Weight (kg) 80.29 (0.53) 78.94 (0.39) 78.69 (0.76) 0.1
Measured Height (cm) 163.93 (0.18) 163.83 (0.19) 163.94 (0.32) 0.9
% Overall Measured Obesity (≥30 kg/m2 Measured BMI) 42.43% 37.89% 38.55% 0.03
% Overall Self-Reported Obesity (≥30 kg/m2 Self-Reported BMI) 43.29% 38.85% 37.66% 0.03
Waist Circumference (cm) 98.41 (0.40) 97.37 (0.31) 97.34 (0.65) 0.09
% Abdominal Measured Obesity (≥120 cm for men; ≥88 cm for women) 56.1% 55.2% 57.1% 0.7
% Body Fat 33.58 (0.21) 32.96 (0.19) 33.18 (0.4) 0.08
% Identified as Diabetic Before or at Baseline Examinationb 14.77% 18.24% 21.01% 0.0002
Unweighted non-diabetic subsample n = 4107 n = 2586 n = 454
Fasting Insulin (mU/L) 11.98 (0.2) 11.96 (0.19) 11.53 (0.47) 0.7
Fasting Glucose (mg/dL) 93.78 (0.18) 94.12 (0.23) 94.67 (0.51) 0.2
HOMA Index of Beta Cell Function 145.17 (2.59) 140.81 (2.33) 133.28 (4.81) 0.07
HOMA Index of Insulin Resistance 2.82 (0.05) 2.84 (0.05) 2.75 (0.12) 0.8
post OGTT Insulin (mU/L)c 78.06 (1.81) 81.09 (1.84) 75.39 (3.2) 0.2
post OGTT, Glucose (mg/dL)c 112.25 (0.78) 114.23 (0.85) 115.85 (1.6) 0.06
Glycated Hemoglobin (mmol/mol) 35.77 (0.1) 35.99 (0.1) 35.72 (0.22) 0.2
% Glycated Hemoglobin 5.42 (0.01) 5.44 (0.01) 5.41 (0.02) 0.2
Unweighted diabeticb subsample n = 933 n = 787 n = 164
Glycated Hemoglobin (mmol/mol) 57.55 (1.25) 57.79 (0.94) 60.06 (2.06) 0.6
% Glycated Hemoglobin 7.42 (0.11) 7.44 (0.09) 7.64 (0.19) 0.6
% Controlled Diabetes (< 7% Glycated Hemoglobin) 26.1% 31.2% 35.3% 0.1
All weighted means and standard deviations (or percentages) for anthropometric measures (weight, height, body mass index, waist circumference, fat percentage,
overall and abdominal obesity) were estimated from regression models, which accounted for the complex sampling design and age, sex, and ancestry
proportions. Additionally, all other weighted means and standard deviations (or percentages) were adjusted for body mass index (BMI) at examination. rs7903146
genotypes were modeled dis-jointly (i.e. no additive model was assumed)
aMeasured and self-reported BMI values at baseline were based off of measured weight and height, and self-reported weight and measured height, respectively
bThe diabetes subsample included individuals reporting having received a previous diabetes diagnosis at baseline examination, or being identified as diabetic at
the baseline examination
c2-h Oral Glucose Tolerance Test (OGTT) was conducted in only individuals who did not report having had a previous diabetes diagnosis
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with both T2D and BMI [3, 10–12], or the apparent statis-
tical interaction between TCF7L2 genotype and adiposity on
T2D related traits seen in previous cross-sectional studies of
US Hispanic/Latinos [31]. Yet, clearly future functional or
longitudinal analyses in population-based samples are re-
quired to substantiate our study’s findings.
Herein, we were also able to explore for the first time to
our knowledge, what might be the direct effect of T2D
diagnosis on subsequent BMI in the context of TCF7L2
genetic effects. The receipt of a T2D diagnosis between 22
and 45 years of age was significantly associated with an
average increase in BMI at 45 years, as compared to those
that never received a diagnosis during this time (Fig. 2).
We did observe a similar, but non-significant association
of T2D diagnosis between 46 and 65 years on BMI at
65 years. This indicates that the possible impact of
pre-diagnosis metabolic dysfunction, T2D-related lifestyle
counseling, or medical intervention also does not fully
explain the apparent negative association between the
TCF7L2 T2D risk allele and BMI [15]. This was further
supported by our non-significant TCF7L2 associations on
BMI at the examination among T2D individuals concur-
rently taking medications (Additional file 1: Table S2).
This current analysis is additionally strengthened by
its focus on adults of varied Hispanic/Latino back-
grounds [45]. Our sampling weights accounted for
non-response and our statistical modeling approach also
allowed us to account for missing data under the as-
sumption of non-informative missingness and to base
our variance calculations on information on the full
population-based sample. In our dataset, missingness
for age-specific BMIs was primarily determined by one’s
age (BMI at 45 and 65 years of age would be missing
for a 35-year-old participant).
Even though a previous study, which did not genotype
rs7903146 directly, has posited that their best marker SNP
at TCF7L2 (rs12255372, r2 = 0.7 in AMR with rs7903146)
may capture a secondary BMI signal in Hispanic/Latinos
[12], subsequent trans-ethnic fine-mapping studies of BMI
and T2D including diverse Hispanic/Latino samples [8, 46]
and large Hispanic/Latino studies have not supported the
presence of multiple signals [47]. This gives us confidence
Table 4 Adjusted Parameter Estimatesa between rs7903146-T and Body Mass Indicesb at the Hispanic Community Health
Study/Study of Latinos Baseline Examination Representing 9031 Individuals (21–76 Years of Age), and at Several Ages Across
the Lifecourse
Sample Sizec Estimated Change in kg/m2 (95% CI) per T2D risk allele P-value
Measured BMI at Examination n = 9012 −0.37 (− 0.69, − 0.06) 0.019
Self-reported BMI at Examination n = 8921 −0.38 (− 0.69, − 0.08) 0.015
Self-reported BMI at 21 Years n = 8759 −0.20 (− 0.45, 0.04) 0.109
Self-reported BMI at 45 Years n = 5605 − 0.18 (− 0.43, 0.06) 0.134
Self-reported BMI at 65 Years n = 729 0.01 (− 0.82, 0.84) 0.980
Abbreviations: BMI Body mass index, T2D Type 2 diabetes, 95% CI 95% confidence interval
aCorresponding to the additive number of T2D risk alleles at TCF7L2 (rs7903146-T) and then adjusted for age, sex, education level, genetic ancestry group and
ancestry proportions
bBody mass index (BMI) was based on self-reported or measured weight in kg, and divided by squared measured height at examination in meters (kg/m2)
cUnweighted sample size differences were a result of individuals missing certain weight measurements. For example, only individuals that were had reached 21,
45 or 65 years of age were asked to provide their weight for that particular age
Table 3 Weighted Mean Body Mass Indices at 45 and 65 years by Categories of Baseline Examination and Diabetes Diagnosis Ages
in the Hispanic Community Health Study/Study of Latinos among Participants > 45 Years of Age (n = 5643)
Unweighted Sample Size BMI (95% CI) at
Age 45 (kg/m2)
BMI (95% CI) at
Age 65 (kg/m2)
Between 46 and 65 Years of Age (n = 4,914)
No Diabetes Diagnosis Reporting at Baseline Examinationa n = 4094 27.49 (27.29, 27.69) –
Diagnosed Between 22 and 45 n = 318 30.36 (29.53, 31.19) –
Diagnosed Between 46 and Age at Examination n = 502 29.30 (28.68, 29.93) –
Between 66 and 76 Years of Age (n = 729)
No Diabetes Diagnosis Reported at Baseline Examinationa n = 502 25.67 (25.16, 26.18) 28.43 (27.72, 29.14)
Diagnosed Between 22 and 45 n = 26 26.51 (25.03, 27.99) 29.71 (27.56, 31.86)
Diagnosed Between 46 and 65 n = 153 27.75 (27.06, 28.45) 30.65 (29.53, 31.77)
Diagnosed Between 66 and Age at Examination n = 48 25.89 (24.71, 27.07) 29.32 (27.58, 31.07)
Abbreviations: BMI body mass index, 95% CI 95% confidence interval
aThis categorization includes individuals who were first diagnosed at the baseline clinic visit
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that rs7903146, the lead variant for the single T2D sig-
nal observed in HCHS/SOL [48], is the best available
SNP marker to simultaneously investigate allelic effects
on BMI and T2D diagnosis within a structural equation
modeling framework. Nonetheless, we do acknowledge
that our current results do not capture all possible sources
of pleiotropy at the TCF7L2 locus, which warrants further
study.
Our structural equation results are also limited by our
reliance on self-reported age of diabetes diagnosis,
instead of repeated quantitative measures of T2D or its
successful control. Among Hispanic/Latinos 15–19 year
old, less than two thirds of diabetes cases may be Type
1, but the type distribution of cases steadily trends
towards more T2D cases into early adulthood [49]—a
period captured in HCHS/SOL. For this reason, we ex-
cluded a small number of individuals reporting early onset
(< 22 years, N = 87) of diabetes. In HCHS/SOL, an add-
itional N = 344 individuals reported a diabetes diagnosed
between 22 and 45 years of age, only 30% of which were
taking insulin by the baseline examination. Without med-
ical or medication histories, we were unable to validate if
these were T2D, or Latent Autoimmune Diabetes in Adults
cases who would be expected to be leaner on average [50].
Nonetheless we take confidence in the observation that the
association of TCF7L2 T2D-risk alleles and BMI was stron-
ger among those without previous T2D diagnosis. In fact,
individuals with impaired glucose tolerance and undiag-
nosed diabetes at examination had the greatest protective
effect on BMI of T2D-risk alleles at TCF7L2. Forthcoming
HCHS/SOL, or other prospective cohort follow up data will
allow future investigators to explore the contemporaneous
and interacting relationships between TCF7L2, BMI and
T2D status across the adult life course.
Similarly, our structural equation modeling was notably
limited by its reliance on self-reported weight histories,
and height measured at the baseline examination to ap-
proximate the BMIs at 21, 45 and 65 years of age. None-
theless this study cohort self-reported their current
weight with good accuracy and reliability at baseline
[34], and we robustly replicated our unstructured
TCF7L2 associations with BMI at examination (21–
76 years) using both measured and self-reported current
weights. Lastly, we cannot rule out the role of birth cohort
or healthy immigrant effects in shaping the characteristics
of our sample of predominantly foreign-born middle-aged
adults, especially among the subset of older adults in
HCHS/SOL (e.g. ≥65 years of age) who were healthy
enough to be community-dwelling at the time of recruit-
ment, and willing to participate in the extensive baseline
examination. Our structured modeling sheds light on this
survival bias, as T2D-risk alleles were non-significantly
associated with an increased BMI at 65 years of age,
independent of earlier BMIs and T2D statuses.
Conclusions
Our significant population-based associations between
T2D risk alleles at TCF7L2 (rs7903146) and lower BMI
do not support selection bias as the sole explanation of
the TCF7L2-BMI association. This work contributes to a
mounting body of literature reporting consistent protect-
ive effects of T2D risk alleles at TCF7L2 and BMI, which
points to a complex mechanistic structure underlying
the functional consequences of TCF7L2 on both T2D
and BMI. Yet, future functional work is needed to
describe the specific cell or tissue types that are most
relevant to the observed TCF7L2 action. Observational
analyses may be particularly useful for estimating causal
effects at this genetic locus and pinpointing windows of
susceptibility for future public health interventions in
populations, like US Hispanic/Latinos, which carry
disproportionate burdens of both T2D and obesity.
Fig. 2 Illustration of structured pathways (effect estimates and standard errors) between the additive number of rs7903146-T alleles, diabetes, and
Body Mass Index (BMI), showing paths with P values < 0.05 in solid lines
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Appendix
Between 2008 and 2011, up to 15 participants per site were
invited to repeat the Hispanic Community Health Study/
Study of Latinos (HCHS/SOL) examination, including the
weight history questionnaire, one to three months after
their initial baseline examination without additional reim-
bursement of their time (N = 56). A total of 52 participants
reported body weights a median of 40 days after their initial
baseline examination (range: 0 to 107 days). The mean dif-
ferences of the 21 and 45-year old self-reported weight
were − 0.9 kg (− 2.7, 1.0) and − 1.3 kg (− 3.8, 1.1) resulting
in good reliabilities and low coefficients of variation
(21-year recall: ICC = 0.89, CV = 7.7% n = 52; 45-year recall:
0.86, 6.7%, n = 29). Only two participants, ≥65 years of age,
recalled their 65-year old weight twice, which precluded
reliability calculations for 65-year old weights.
HCHS/SOL personnel (requiring a minimum of 5
practice subjects with 0.5 kg weight and 0.5 cm height
agreement between a trainee and expert) measured height
(cm) and weight (kg) during the anthropometric examin-
ation of the full HCHS/SOL cohort using a fixed (wall
mounted) stadiometer (inspected daily) and a digital scale
(scales zero balanced daily and calibrated weekly) on all
participants that were able to stand on both feet while
wearing a scrub suit or examination gown and no shoes
[34]. Currently pregnant women were rescheduled for the
HCHS/SOL baseline examination approximately 3 months
after their delivery. The validity of self-reported weight, and
inter-rater reliability of self-reported weight, measured
weight and height have been reported to be good for the
HCHS/SOL baseline examination [34].
HCHS/SOL study personnel were centrally trained and
periodically observed. In addition we applied a data quality
control protocol, as described previously for self-reported
current weight collected as part of the anthropometric
examination [34] to 1) minimize potential instances of unit
confusion in the self-report (lb versus kg) or 2) exclude
self-reported weights during pregnancy reported during the
baseline examination, self-reported or measured weights
made by individuals with past limb amputation or when
scaled by measured baseline height that correspond to ex-
treme underweight (< 16 kg/m2) or obesity (> 70 kg/m2).
However, herein, we extended this protocol to also include
recalled weights at 21, 45, or 65 years of age. We first
flagged entire weight histories with either a ≥ 15 kg differ-
ence between current self-reported and measured weight,
or at least two ≥15 kg pairwise fluctuations in weight
(Additional file 1: Figure S1 and Table S1). Of the entire
set of 16,355 individuals with at least one self-reported
weight in adulthood (40,525 observations) and based on
our staged quality control protocol, we recoded a total of 54
observations, and excluded an additional 541 observations
(Additional file 1: Table S1). Only six self-reported weights
from the anthropometric examination (age range 27–
64 years) were recoded and retained in our final analytic
sample.
Additional file
Additional file 1: Figure S1. LDlink plot showing the regional r2
patterning between 1000 Genomes AMR and EUR reference populations
at TCF7L2 around rs7903146 (shown in blue) and rs12255372 (alternative
marker of the rs7903146 signal), with the bubble size representing the
frequency of each SNP and the support for each SNP’s regulatory
potential shown numerically (strong to weak: 1–7 RegulomeDB Scores).
Table S1 Staged data cleaning and outlier identification on total sample
of 40,525 self-reported weights from 16,355 adult participants (18–76 years)
in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).
Figure S2. Flow chart of staged quality control on 16,355 adult Hispanic/
Latino participants (18–76 years) with at least one self-reported weight, as
part of the anthropometric exam or weight history questionnaire, at the
baseline examination (2008–2011) of the Hispanic Community Health
Study/Study of Latinos (HCHS/SOL), resulting in 54 self-reported weights
recoded due to unit confusion, 541 individuals excluded, and a final analytic
sample of 16,322 participants. Table S2. Parameter Estimates of the Effect
per Type 2 Diabetes Risk Allele (rs7903146-T) in a Multivariable Model Using
Measured and Self-Reported Weight Measurements in the Analytic Sample
Stratified by Diabetes Status at Baseline Examination and Medication.
Figure S3. Illustration of all possible pathways in Structural Equation
Model. Table S3. Parameter Estimates from Pathway Model Results.
Table S4. Parameter Estimates for Select Indeirect Pathway Model Results.
(DOCX 787 kb)
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